... allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma...

...Salvatore Troisi; Valentina Giudice; Mario Troisi; Denise Morini; Andrea Crudele; Bianca Cuffa; Carmine Selleri; Bianca Serio Daratumumab, an anti-CD38 monoclonal antibody, is worldwide approved for treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM) patients and is available...

...Kazuhito Suzuki; Morio Matsumoto; Yasushi Hiramatsu; Naoki Takezako; Yotaro Tamai; Kenshi Suzuki Introduction: Elotuzumab and lenalidomide plus dexamethasone (ERd) is a standard salvage chemotherapy for multiple myeloma, and elotuzumab is commonly administered every 2 weeks after cycle 3...

...) and lymphoproliferative disorders, such as lymphomas. Instead, since the association with plasma cell diseases such as multiple myeloma and plasmacytoma is infrequent, there is a lack of literature. This manuscript aimed to revise the literature by describing a rare case of CD and plasmacytoma and attempting to explain...

... multiple myeloma (SMM, n = 2) and low-risk monoclonal gammopathy of undetermined significance (MGUS, n = 6). Six patients were on tyrosine kinase inhibitor treatment, 2 were in treatment-free remission. The only covariate associated with paraproteinemia was the presence of anemia, albeit with borderline...

... and prognostic value of multiple myeloma (MM). MYC gene-related abnormalities (MYC GAs) are one of the CAs, but their unfavorable impact has not been fully investigated in daily clinical practice. Methods: This study retrospectively analyzed the prognostic impact of MYC GAs on 81 patients through fluorescence...

...Josefin Hidman; Anders Larsson; Måns Thulin; Torbjörn Karlsson Introduction: In multiple myeloma, there is an increase in bone marrow microvascular density and enhanced renal lymphangiogenesis. Increased levels of the proangiogenic protein growth differentiation factor-15 (GDF15) have previously...

...Congyang Huang; Hanshan Liu; Li Jia; Min Lu; Suyun Hu Background/Aim: The impacts of health insurance status on survival outcomes in multiple myeloma (MM) have not been addressed in depth. The present study was conducted to identify definite relationships of cancer-specific survival (CSS...

...Hareth Nahi; Göran Walinder; Vishal Patel; Ying Qu; Aaron Levine; Istvan Majer; Lucie Kutikova; Eva Hellqvist Franck; Maria K. Svensson; Markus Hansson Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world...

... study in relapsed/refractory multiple myeloma (MM). Here, we present data from a phase II study (NCT02290431) of this combination in Japanese patients with relapsed or relapsed-and-refractory MM. Methods: Patients received 3-week cycles of 20-mg oral panobinostat (weeks 1 and 2), 1.3-mg/m 2 subcutaneous...

...Laura Notarfranchi; Valentina Marchica; Benedetta Dalla Palma; Laura Pelagatti; Jessica Burroughs-Garcia; Mario Pedrazzoni; Livia Ruffini; Filomena Cetani; Claudio Marcocci; Nicola Giuliani Hypercalcemia is a significant feature of patients with active multiple myeloma (MM) with extensive bone...

... between ESA and glucose in anemia-treated patients with myelodysplastic syndromes (MDS) or multiple myeloma (MM). Patients and Methods: Patients’ glucose levels were compared while on to while off ESA, and all served as their own controls. To test the association between ESA and blood glucose, we employed...

...Yang Liu; Lei Wen; Huan Chen; Yao Chen; Wenbing Duan; Ying Kang; Ling Ma; Xiaojun Huang; Jin Lu Background: Serum lactate dehydrogenase (LDH) is an adverse prognostic factor for newly diagnosed multiple myeloma (MM). However, the role of LDH in the prognosis of MM patients with relapse has not yet...

...Abdullah S. Al Saleh; Taimur Sher; Morie A. Gertz We provide our recommendations (not evidence based) for managing multiple myeloma patients during the pandemic of COVID-19. We do not recommend therapy for smoldering myeloma patients (standard or high risk). Screening for COVID-19 should be done...

... and immunotherapy is increasingly recognized. Plasma cells in multiple myeloma have the potential to survive in the gastrointestinal tract for long periods of time. The nature of the gut microbiota impacts the degree of antigen stimulation of these cells and may play a role in mutation development and clonal...

...: The treatment of patients with multiple myeloma (MM) has evolved in recent years, and the disease-associated prognosis has improved substantially. This improvement has been driven largely by the approval of novel agents, many of which are expensive and not universally available. Less expensive but effective...

... gene 18 ( SNHG18 ) andsemaphorin 5A ( SEMA5A ) genes in multiple myeloma (MM) patients and to explore the correlation of the expression of these genes with the clinical characteristics and prognosis of MM patients. Methods: Forty-seven newly diagnosed MM, 18 complete remission MM, 13 refractory/relapse...

...Pu Xiang; Yuzhang Liu; Lina Liu; Quande Lin; Xiyang Liu; Hongmei Zhang; Jie Xu; Baijun Fang Background: miR-886-5p plays an important role in many tumors, but it has been rarely investigated in multiple myeloma (MM). We studied the expression of miR-886-5p in the plasma of MM patients and in MM...

... transplantation (ASCT) in newly diagnosed Japanese patients with multiple myeloma (MM). This regimen consisted of four 28-day cycles of once-weekly oral cyclophosphamide (300 mg/m 2 ), subcutaneous bortezomib (1.3 mg/m 2 ), and oral dexamethasone (40 mg). Responding patients underwent stem cell collection...

... Matutes Multiparameter flow cytometry (MFC)-based clonality assessment is a powerful method of diagnosis and follow-up in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). However, the relevance of intraclonal heterogeneity in immunophenotypic studies remains poorly...